文献速递系统性红斑狼疮

系统性红斑狼疮患者难治性高血压发病率升高:一项回顾性队列研究

Increased Incidence of Resistant Hypertension in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2020-01-01

该回顾性队列研究基于三级医疗中心电子健康记录,比较1,044例SLE患者与5,241例对照的难治性高血压(RHTN)风险,并分析SLE患者中RHTN与全因死亡的关系。结果显示SLE患者RHTN患病率近两倍于对照(10.2% vs 5.3%),发生率10.2 vs 6.1例/1000人年(HR 1.72,95%CI 1.28-2.30,P<0.001),且RHTN与显著更高的死亡风险相关(HR 2.91,P=0.0005)。

要点

  • SLE患者RHTN患病率10.2%,对照5.3%,风险独立于多变量。
  • SLE患者RHTN发生率10.2 vs 6.1例/1000人年,HR 1.72。
  • SLE患者中RHTN与全因死亡风险升高相关(HR 2.91)。

核心结论

  • SLE患者较频率匹配的对照有更高的RHTN风险,且独立于多个协变量。
  • RHTN是SLE患者中与更高死亡风险相关的重要合并症,临床医生应识别。

研究设计与样本

  • 回顾性队列研究,使用三级医疗中心去标识电子健康记录。
  • 纳入1,044例SLE患者和5,241例对照;SLE定义为≥4个ICD-9编码且ANA滴度≥1:160。
  • RHTN定义为使用3种降压药血压未控制或需≥4种降压药达标。

主要发现

  • SLE患者RHTN患病率10.2%,对照5.3%。
  • RHTN发生率SLE组10.2例/1000人年,对照组6.1例/1000人年。
  • 调整年龄、性别、种族、基线ESRD、肌酐和日历年后的HR为1.72(95%CI 1.28-2.30),P<0.001。
  • SLE患者中RHTN与黑种人、较低肾功能、高胆固醇血症和炎症标志物升高相关。
  • 调整年龄、性别、种族、日历年、肌酐、基线ESRD和就诊次数后,RHTN与死亡风险升高相关(HR 2.91,P=0.0005)。

关键数值与推荐

  • SLE定义:≥4个ICD-9编码且ANA滴度≥1:160。
  • RHTN定义:使用3种降压药血压未控制或需≥4种降压药达标。
  • RHTN与死亡风险的调整后HR为2.91(P=0.0005)。

临床怎么用

  • 在SLE患者中应识别RHTN,因其与更高死亡风险相关。
  • 对SLE患者,尤其合并黑种人、肾功能下降、高胆固醇血症或炎症标志物升高者,需关注RHTN风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the risk of resistant hypertension (RHTN) in patients with systemic lupus erythematosus (SLE) and in controls without SLE, and to define factors associated with RHTN in patients with SLE. METHODS: We studied 1,044 patients with SLE and 5,241 control subjects using de-identified electronic health records from a tertiary care center. SLE was defined as ≥4 International Classification of Diseases, Ninth Revision codes for SLE and antinuclear antibody titer ≥1:160. RHTN was defined as uncontrolled blood pressure on 3 antihypertensive medications or requiring 4 or more antihypertensives to attain control. First, we compared the risk of RHTN between groups. Second, we examined the association between RHTN and all-cause mortality in patients with SLE. RESULTS: RHTN was nearly twice as prevalent in patients with SLE compared to control subjects (10.2% and 5.3%, respectively), with an incidence rate of 10.2 versus 6.1 cases per 1,000 person-years of observation (hazard ratio [HR] 1.72 [95% confidence interval 1.28-2.30]; P < 0.001, adjusted for age, sex, race, baseline end-stage renal disease [ESRD], creatinine, and calendar year). In patients with SLE, we found associations between RHTN and black race, lower renal function, hypercholesterolemia, and increased inflammatory markers. RHTN was associated with a significantly higher mortality risk (HR 2.91, P = 0.0005) after adjustment for age, sex, race, calendar year, creatinine, baseline ESRD, and number of visits. CONCLUSION: Patients with SLE have a higher risk of RHTN compared to frequency-matched controls, independent of multiple covariates. RHTN is an important comorbidity for clinicians to recognize in SLE, because it is associated with a higher risk of mortality.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Gandelman JS, Khan OA, Shuey MM, et al. Increased Incidence of Resistant Hypertension in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study. Arthritis Care Res (Hoboken). 2020. PMID: 30875459. doi:10.1002/acr.23880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。